In our study, participants in the IBD cohort were in clinical remission with a median CRP and FC within the normal range; however, a higher CRP correlated with higher serum insulin and triglyceride levels, a higher BMI and waist circumference, and a lower HDL level, suggesting that in the absence of active gastrointestinal disease, elevated CRP may be a marker of metabolic risk. The gene discussed is INS; the disease is gastrointestinal disease.